Wyeth/Progenics’ Relistor Fails Second Phase III POI Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Companies also report positive Phase II results for an oral formulation in opioid-induced constipation.
You may also be interested in...
Who Stays, Who Goes? Tricky Guessing On Wyeth/Pfizer’s Keeper Deals
"Buyer beware" is more often "seller beware" in the case of takeovers such as Pfizer's proposed mega-grab of Wyeth
Who Stays, Who Goes? Tricky Guessing On Wyeth/Pfizer’s Keeper Deals
"Buyer beware" is more often "seller beware" in the case of takeovers such as Pfizer's proposed mega-grab of Wyeth
Tranzyme’s TZP-101 Proof-of-Concept Study Bodes Well For Deal, CEO Says
Compound’s promising Phase IIb results should pave the way to an exit for the North Carolina biotech.